- Home
- ABTS vs BLRX Comparison
ABTS vs BLRX Comparison
Compare ABTS & BLRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ABTS
- BLRX
- Stock Information
- Founded
- ABTS 2010
- BLRX 2003
- Country
- ABTS Hong Kong
- BLRX Israel
- Employees
- ABTS N/A
- BLRX N/A
- Industry
- ABTS Computer Software: Programming Data Processing
- BLRX Biotechnology: Pharmaceutical Preparations
- Sector
- ABTS Technology
- BLRX Health Care
- Exchange
- ABTS Nasdaq
- BLRX Nasdaq
- Market Cap
- ABTS 15.9M
- BLRX 17.3M
- IPO Year
- ABTS N/A
- BLRX 2011
- Fundamental
- Price
- ABTS $0.47
- BLRX $3.48
- Analyst Decision
- ABTS
- BLRX Strong Buy
- Analyst Count
- ABTS 0
- BLRX 2
- Target Price
- ABTS N/A
- BLRX $5.50
- AVG Volume (30 Days)
- ABTS 76.0K
- BLRX 432.3K
- Earning Date
- ABTS 12-31-2024
- BLRX 03-25-2025
- Dividend Yield
- ABTS N/A
- BLRX N/A
- EPS Growth
- ABTS N/A
- BLRX N/A
- EPS
- ABTS N/A
- BLRX N/A
- Revenue
- ABTS $5,343,888.00
- BLRX $21,991,000.00
- Revenue This Year
- ABTS N/A
- BLRX N/A
- Revenue Next Year
- ABTS N/A
- BLRX N/A
- P/E Ratio
- ABTS N/A
- BLRX N/A
- Revenue Growth
- ABTS 3970.67
- BLRX N/A
- 52 Week Low
- ABTS $0.38
- BLRX $0.08
- 52 Week High
- ABTS $1.07
- BLRX $4.44
- Technical
- Relative Strength Index (RSI)
- ABTS 46.52
- BLRX 92.08
- Support Level
- ABTS $0.44
- BLRX $3.24
- Resistance Level
- ABTS $0.59
- BLRX $3.70
- Average True Range (ATR)
- ABTS 0.04
- BLRX 0.17
- MACD
- ABTS -0.00
- BLRX 0.41
- Stochastic Oscillator
- ABTS 21.85
- BLRX 77.98
About ABTS Abits Group Inc
Abits Group Inc is a digital data center operator with bitcoin self-mining operations.
About BLRX BioLineRx Ltd.
BioLine Rx Ltd is a commercial-stage biopharmaceutical company focused on oncology. The company's current development and commercialization pipeline consists of two clinical-stage therapeutic candidates motixafortide (BL-8040), a novel peptide for the treatment of stem-cell mobilization and solid tumors, and AGI-134, an immuno-oncology agent in development for solid tumors. In addition, the company has an off-strategy, legacy therapeutic product called BL-5010 for the treatment of skin lesions. The company has generated revenues from milestone payments under previously existing out-licensing agreements.